Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Update

by · The Cerbat Gem

Klotho Neurosciences, Inc. (NASDAQ:KLTO – Get Free Report) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 248,611 shares, a decrease of 50.3% from the November 30th total of 500,273 shares. Based on an average trading volume of 748,749 shares, the short-interest ratio is presently 0.3 days. Currently, 0.5% of the shares of the stock are short sold. Currently, 0.5% of the shares of the stock are short sold. Based on an average trading volume of 748,749 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Read Our Latest Report on Klotho Neurosciences

Klotho Neurosciences Price Performance

NASDAQ KLTO traded down $0.02 on Friday, reaching $0.35. The company had a trading volume of 612,647 shares, compared to its average volume of 700,536. The firm has a market cap of $25.14 million, a price-to-earnings ratio of -1.08 and a beta of 10.05. Klotho Neurosciences has a fifty-two week low of $0.11 and a fifty-two week high of $3.91. The business has a 50 day moving average of $0.46 and a two-hundred day moving average of $0.76.

Klotho Neurosciences (NASDAQ:KLTO – Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.05) earnings per share for the quarter.

Hedge Funds Weigh In On Klotho Neurosciences

An institutional investor recently bought a new position in Klotho Neurosciences stock. Jane Street Group LLC purchased a new position in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO – Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned 0.05% of Klotho Neurosciences at the end of the most recent quarter. Institutional investors and hedge funds own 20.07% of the company’s stock.

Klotho Neurosciences Company Profile

(Get Free Report)

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.

Recommended Stories